Adjuvant T-DM1 improved IDFS in HER2-positive early breast cancer patients with residual invasive disease

San Antonio Breast Cancer Symposium 2018 Press Release Dec 06, 2018

Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2- positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4–8.


“HER2-positive breast cancers account for about 15...

Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.